Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Publication
, Journal Article
Stout, JE
Published in: Expert Opin Drug Saf
May 2004
A 2-month regimen of rifampin and pyrazinamide (2RZ) became an accepted alternative for treatment of latent tuberculosis (TB) after initial studies in HIV-seropositive patients demonstrated safety and efficacy. Once this alternative came into widespread use, however, a number of cases of severe and fatal hepatitis associated with 2RZ were reported. Although the initial experience with HIV-seropositive patients was encouraging, subsequent research demonstrated that the risk of 2RZ-associated hepatitis is considerably greater than the risk of hepatitis associated with isoniazid treatment for latent TB. Updated guidelines now recommend only restricted use of the 2RZ regimen for latent TB, with careful supervision.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Expert Opin Drug Saf
DOI
ISSN
1474-0338
Publication Date
May 2004
Volume
3
Issue
3
Start / End Page
187 / 198
Location
England
Related Subject Headings
- Tuberculosis, Pulmonary
- Rifampin
- Randomized Controlled Trials as Topic
- Pyrazinamide
- Pharmacology & Pharmacy
- Isoniazid
- Humans
- Drug Therapy, Combination
- Antitubercular Agents
- Antibiotics, Antitubercular
Citation
APA
Chicago
ICMJE
MLA
NLM
Stout, J. E. (2004). Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opin Drug Saf, 3(3), 187–198. https://doi.org/10.1517/eods.3.3.187.31073
Stout, Jason E. “Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.” Expert Opin Drug Saf 3, no. 3 (May 2004): 187–98. https://doi.org/10.1517/eods.3.3.187.31073.
Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opin Drug Saf. 2004 May;3(3):187–98.
Stout, Jason E. “Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.” Expert Opin Drug Saf, vol. 3, no. 3, May 2004, pp. 187–98. Pubmed, doi:10.1517/eods.3.3.187.31073.
Stout JE. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opin Drug Saf. 2004 May;3(3):187–198.
Published In
Expert Opin Drug Saf
DOI
ISSN
1474-0338
Publication Date
May 2004
Volume
3
Issue
3
Start / End Page
187 / 198
Location
England
Related Subject Headings
- Tuberculosis, Pulmonary
- Rifampin
- Randomized Controlled Trials as Topic
- Pyrazinamide
- Pharmacology & Pharmacy
- Isoniazid
- Humans
- Drug Therapy, Combination
- Antitubercular Agents
- Antibiotics, Antitubercular